Literature DB >> 22972997

Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons.

Iryna A Khasabova1, Yee Xiong, Lia G Coicou, Daniele Piomelli, Virginia Seybold.   

Abstract

The amplitude of the depolarization-evoked Ca2+ transient is larger in dorsal root ganglion (DRG) neurons from tumor-bearing mice compared with that of neurons from naive mice, and the change is mimicked by coculturing DRG neurons with the fibrosarcoma cells used to generate the tumors (Khasabova et al., 2007). The effect of palmitoylethanolamide (PEA), a ligand for the peroxisome proliferator-activated receptor α (PPARα), was determined on the evoked-Ca2+ transient in the coculture condition. The level of PEA was reduced in DRG cells from tumor-bearing mice as well as those cocultured with fibrosarcoma cells. Pretreatment with PEA, a synthetic PPARα agonist (GW7647), or ARN077, an inhibitor of the enzyme that hydrolyzes PEA, acutely decreased the amplitude of the evoked Ca2+ transient in small DRG neurons cocultured with fibrosarcoma cells. The PPARα antagonist GW6471 blocked the effect of each. In contrast, the PPARα agonist was without effect in the control condition, but the antagonist increased the amplitude of the Ca2+ transient, suggesting that PPARα receptors are saturated by endogenous ligand under basal conditions. Effects of drugs on mechanical sensitivity in vivo paralleled their effects on DRG neurons in vitro. Local injection of ARN077 decreased mechanical hyperalgesia in tumor-bearing mice, and the effect was blocked by GW6471. These data support the conclusion that the activity of DRG neurons is rapidly modulated by PEA through a PPARα-dependent mechanism. Moreover, agents that increase the activity of PPARα may provide a therapeutic strategy to reduce tumor-evoked pain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972997      PMCID: PMC3462371          DOI: 10.1523/JNEUROSCI.0130-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  45 in total

1.  Activation of protein kinase C in sensory neurons accelerates Ca2+ uptake into the endoplasmic reticulum.

Authors:  Yuriy M Usachev; Anthony J Marsh; Tanner M Johanns; Michelle M Lemke; Stanley A Thayer
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

2.  Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP.

Authors:  H Cadas; S Gaillet; M Beltramo; L Venance; D Piomelli
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

3.  Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology.

Authors:  T Meuser; C Pietruck; L Radbruch; P Stute; K A Lehmann; S Grond
Journal:  Pain       Date:  2001-09       Impact factor: 6.961

4.  Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647.

Authors:  Roberto Russo; Jesse LoVerme; Giovanna La Rana; Giuseppe D'Agostino; Oscar Sasso; Antonio Calignano; Daniele Piomelli
Journal:  Eur J Pharmacol       Date:  2007-03-19       Impact factor: 4.432

5.  N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase.

Authors:  Kazuhito Tsuboi; Christine Hilligsmann; Séverine Vandevoorde; Didier M Lambert; Natsuo Ueda
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

Review 6.  Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease.

Authors:  S E O'Sullivan; D A Kendall
Journal:  Immunobiology       Date:  2009-10-14       Impact factor: 3.144

7.  Bone cancer pain.

Authors:  Denis R Clohisy; Patrick W Mantyh
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

8.  A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain.

Authors:  Iryna A Khasabova; Sergey G Khasabov; Catherine Harding-Rose; Lia G Coicou; Bryan A Seybold; Amy E Lindberg; Christopher D Steevens; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2008-10-29       Impact factor: 6.167

9.  Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain.

Authors:  Matthias Schweizerhof; Sebastian Stösser; Martina Kurejova; Christian Njoo; Vijayan Gangadharan; Nitin Agarwal; Martin Schmelz; Kiran Kumar Bali; Christoph W Michalski; Stefan Brugger; Anthony Dickenson; Donald A Simone; Rohini Kuner
Journal:  Nat Med       Date:  2009-06-07       Impact factor: 53.440

10.  Modulation of transient receptor potential Vanilloid 4-mediated membrane currents and synaptic transmission by protein kinase C.

Authors:  De-Shou Cao; Shuang-Quan Yu; Louis S Premkumar
Journal:  Mol Pain       Date:  2009-02-10       Impact factor: 3.395

View more
  33 in total

1.  A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation.

Authors:  Alison Ribeiro; Silvia Pontis; Luisa Mengatto; Andrea Armirotti; Valerio Chiurchiù; Valeria Capurro; Annalisa Fiasella; Andrea Nuzzi; Elisa Romeo; Guillermo Moreno-Sanz; Mauro Maccarrone; Angelo Reggiani; Giorgio Tarzia; Marco Mor; Fabio Bertozzi; Tiziano Bandiera; Daniele Piomelli
Journal:  ACS Chem Biol       Date:  2015-04-15       Impact factor: 5.100

Review 2.  Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.

Authors:  Stephen D Skaper; Laura Facci; Mariella Fusco; Maria Federica Della Valle; Morena Zusso; Barbara Costa; Pietro Giusti
Journal:  Inflammopharmacology       Date:  2013-11-01       Impact factor: 4.473

Review 3.  A lipid gate for the peripheral control of pain.

Authors:  Daniele Piomelli; Andrea G Hohmann; Virginia Seybold; Bruce D Hammock
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 4.  Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.

Authors:  Daniel J Hermanson; Joyonna C Gamble-George; Lawrence J Marnett; Sachin Patel
Journal:  Trends Pharmacol Sci       Date:  2014-05-18       Impact factor: 14.819

Review 5.  The endocannabinoid system - a target for the treatment of LUTS?

Authors:  Petter Hedlund; Christian Gratzke
Journal:  Nat Rev Urol       Date:  2016-07-05       Impact factor: 14.432

6.  Activity-Based Probe for N-Acylethanolamine Acid Amidase.

Authors:  Elisa Romeo; Stefano Ponzano; Andrea Armirotti; Maria Summa; Fabio Bertozzi; Gianpiero Garau; Tiziano Bandiera; Daniele Piomelli
Journal:  ACS Chem Biol       Date:  2015-06-23       Impact factor: 5.100

Review 7.  Advances in the discovery of N-acylethanolamine acid amidase inhibitors.

Authors:  Tiziano Bandiera; Stefano Ponzano; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2014-05-04       Impact factor: 7.658

Review 8.  Peripheral gating of pain signals by endogenous lipid mediators.

Authors:  Daniele Piomelli; Oscar Sasso
Journal:  Nat Neurosci       Date:  2014-01-28       Impact factor: 24.884

Review 9.  A fatty gut feeling.

Authors:  Daniele Piomelli
Journal:  Trends Endocrinol Metab       Date:  2013-04-06       Impact factor: 12.015

10.  3-Aminoazetidin-2-one derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors suitable for systemic administration.

Authors:  Annalisa Fiasella; Andrea Nuzzi; Maria Summa; Andrea Armirotti; Glauco Tarozzo; Giorgio Tarzia; Marco Mor; Fabio Bertozzi; Tiziano Bandiera; Daniele Piomelli
Journal:  ChemMedChem       Date:  2014-05-14       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.